Retatrutide: The Triple Agonist for Weight Loss

Retatrutide

28.7%

In the first phase 3 trial (TRIUMPH-4), retatrutide 12 mg produced 28.7% mean body weight reduction at 68 weeks, translating to an average loss of 71.2 lbs.

Eli Lilly, TRIUMPH-4 Phase 3 Results, December 2025

Eli Lilly, TRIUMPH-4 Phase 3 Results, December 2025

View as image

Retatrutide is the first triple hormone receptor agonist to reach phase 3 clinical trials for obesity. It activates GLP-1, GIP, and glucagon receptors in a single molecule, producing the largest weight reductions reported for any anti-obesity peptide in clinical development. Phase 2 data published in the New England Journal of Medicine showed 24.2% mean weight loss at 48 weeks. Phase 3 topline data from December 2025 pushed that to 28.7% at 68 weeks, an average loss of 71.2 lbs. The drug is not yet approved. This article covers what the clinical evidence shows, where the risks are, and how retatrutide fits into the broader weight loss pipeline. For details on its mechanism, see How Retatrutide Targets Three Receptors at Once. For the pillar overview of retatrutide across all its applications, see Retatrutide and Liver Fat.

How Retatrutide Works

Retatrutide (LY3437943) activates three metabolic hormone receptors:

GLP-1 receptor: Suppresses appetite through hypothalamic signaling, slows gastric emptying, and enhances insulin secretion. This is the same target as semaglutide (Ozempic/Wegovy) and the GLP-1 component of tirzepatide (Mounjaro/Zepbound).

GIP receptor: Enhances the insulin response to meals, improves lipid metabolism, and may contribute to weight loss through mechanisms still under investigation. GIP receptor agonism is shared with tirzepatide.

Glucagon receptor: Increases hepatic fatty acid oxidation, stimulates energy expenditure, and reduces liver fat. This is the component unique to retatrutide. Glucagon normally raises blood sugar, but in combination with GLP-1 and GIP agonism, the glucose-raising effect is counterbalanced by enhanced insulin signaling.^[3]

The triple agonist hypothesis holds that combining all three receptor targets in one molecule produces additive or synergistic metabolic benefits. The clinical data so far supports this: retatrutide produces larger weight reductions, greater liver fat clearance, and broader metabolic improvements than mono- or dual-agonist peptides in comparable trial designs.

Phase 2 Obesity Trial (NEJM, 2023)

Jastreboff et al. published the foundational retatrutide obesity data in the New England Journal of Medicine.^[1]

Design: Phase 2, double-blind, randomized, placebo-controlled. 338 adults with BMI 30+ (or 27+ with a weight-related condition). 51.8% men. Participants were randomized to weekly subcutaneous retatrutide (1, 4, 8, or 12 mg) or placebo for 48 weeks.

24-week results (primary endpoint):

• Placebo: -1.6%
• 1 mg: -7.2%
• 4 mg (combined): -12.9%
• 8 mg (combined): -17.3%
• 12 mg: -17.5%

48-week results:

• Placebo: -2.1%
• 1 mg: -8.7%
• 4 mg: -17.1%
• 8 mg: -22.8%
• 12 mg: -24.2%

At 48 weeks with the 12 mg dose, 100% of participants lost at least 5% of body weight, 93% lost at least 10%, and 83% lost at least 15%. Weight loss had not fully plateaued by week 48, suggesting further reduction with longer treatment.

Safety: The most common adverse events were gastrointestinal (nausea, diarrhea, vomiting), dose-related, and mostly mild to moderate. Starting at 2 mg rather than 4 mg partially mitigated early GI symptoms. Dose-dependent heart rate increases peaked at 24 weeks and declined thereafter.

Phase 2 Type 2 Diabetes Trial (Lancet, 2023)

Rosenstock et al. evaluated retatrutide in people with type 2 diabetes in a parallel phase 2 program.^[3]

The trial enrolled adults aged 18-75 with T2D, HbA1c 7.0-10.5%, and BMI 25-50. Retatrutide produced clinically meaningful improvements in glycemic control alongside robust weight reductions. HbA1c reductions were significant across dose groups, confirming that the triple agonist mechanism addresses both weight and blood sugar.

This matters because most people with severe obesity also have insulin resistance or type 2 diabetes. A drug that effectively treats both conditions simultaneously has obvious clinical advantages over treating each separately. The clinical trial results article provides deeper analysis of the dose-response data across both trials.

Phase 3: TRIUMPH-4 Results (December 2025)

In December 2025, Eli Lilly released topline results from TRIUMPH-4, the first completed phase 3 trial for retatrutide. The study enrolled adults with obesity or overweight who also had knee osteoarthritis.

Weight loss results at 68 weeks:

• Retatrutide 9 mg: -26.4% mean body weight loss
• Retatrutide 12 mg: -28.7% mean body weight loss (average 71.2 lbs)
• Placebo: not disclosed in topline data

These results exceeded the phase 2 data, which was expected given the longer treatment duration (68 vs. 48 weeks). At 28.7%, retatrutide produced the largest average weight reduction reported for any anti-obesity drug in a phase 3 trial.

Additional findings:

• Significant reduction in knee osteoarthritis pain scores
• Reduced non-HDL cholesterol, triglycerides, and hsCRP (cardiovascular risk markers)
• Systolic blood pressure reduced by 14.0 mmHg at the highest dose

Safety concerns:

• Discontinuation due to adverse events: 12.2% (9 mg), 18.2% (12 mg), 4.0% (placebo). Among participants with baseline BMI 35+, rates were lower: 8.8% and 12.1%.
• Nausea: 38.1% (9 mg), 43.2% (12 mg), 10.7% (placebo)
• Diarrhea: 34.7% (9 mg), 33.1% (12 mg), 13.4% (placebo)
• Dysesthesia (abnormal sensation): 8.8% (9 mg), 20.9% (12 mg), 0.7% (placebo). This is a new safety signal not prominent in phase 2 data. The events were generally mild and rarely led to discontinuation, but the dose-dependent pattern requires monitoring in ongoing trials.

These are topline results from a press release. Peer-reviewed publication with full data, including detailed subgroup analyses and quality-of-life measures, is pending. Seven additional TRIUMPH phase 3 readouts are expected in 2026, including studies on maintenance dosing strategies and specific patient populations.

Pooled Evidence: What the Meta-Analysis Shows

Abdrabou et al. (2025) published a systematic review and meta-analysis of retatrutide across three randomized controlled trials encompassing 878 patients.^[4]

Pooled results showed retatrutide significantly reduced:

• Body weight: mean difference -14.33% (P < 0.00001)
• BMI: -5.38 (P < 0.00001)
• Waist circumference: -10.51 cm (P < 0.00001)
• Fasting plasma glucose: -23.51 mg/dL (P < 0.00001)
• HbA1c: -0.91% (P < 0.00001)
• Blood pressure: statistically significant reductions (P < 0.00001)

The meta-analysis confirmed a dose-dependent relationship, with 12 mg producing maximum reductions across all measured outcomes. The safety profile was consistent across trials, with GI events being the primary concern.

How It Compares

No head-to-head trials have been conducted between retatrutide and its competitors. Cross-trial comparisons are imperfect due to differences in patient populations, trial duration, and endpoints. With that caveat, the approximate weight loss landscape at comparable timepoints:

Retatrutide's additional weight loss over tirzepatide is roughly 6 percentage points. Whether this incremental benefit justifies the additional safety burden (higher discontinuation rates, the dysesthesia signal) is a clinical question that cannot be answered from current data alone. The retatrutide vs. tirzepatide vs. semaglutide comparison article covers this in more detail.

A Bayesian network meta-analysis of 19 randomized controlled trials (29,506 adults) found that retatrutide and dual agonists achieved equivalent mean weight loss (-11.0 kg), but retatrutide excelled at achieving the deepest weight loss thresholds (15%+ body weight reduction). This suggests the triple mechanism may particularly benefit patients who need the largest absolute weight reductions.

The safety comparison is equally important. Tirzepatide's discontinuation rate due to adverse events in SURMOUNT trials was approximately 4-7%, substantially lower than retatrutide's 12-18%. Semaglutide's rates are similar to tirzepatide's. The additional efficacy of retatrutide comes with a measurably higher tolerability cost, and the dysesthesia signal has no parallel in the GLP-1 or dual agonist class.

The Liver Bonus

Unlike single or dual agonists, retatrutide produces dramatic liver fat reduction. In the MASLD substudy, Sanyal et al. (2024) reported up to 86% relative liver fat reduction at 48 weeks, with 93% of participants on 12 mg achieving normal liver fat levels.^[2] This effect appears driven by the glucagon receptor component stimulating hepatic fatty acid oxidation, as evidenced by 2-3 fold increases in beta-hydroxybutyrate levels. For a full analysis of the liver data, see Retatrutide and Liver Fibrosis: Triple Agonist Data.

What Remains Unknown

Long-term safety beyond 68 weeks: The longest published data is 48 weeks (phase 2). TRIUMPH-4 extends to 68 weeks. What happens with years of treatment is unknown. The dysesthesia signal warrants particular long-term monitoring.

Weight regain after stopping: No published data exists on what happens to weight when retatrutide is discontinued. Based on experience with GLP-1 agonists, substantial regain is expected.

Cardiovascular outcomes: Retatrutide reduces cardiovascular risk markers (blood pressure, lipids, hsCRP), but no dedicated cardiovascular outcomes trial has been completed. This data is critical given the heart rate elevation seen in trials.

Muscle mass preservation: At 28.7% weight loss, muscle loss is a serious concern. In typical weight loss, roughly 25-40% of lost weight comes from lean mass rather than fat. A body composition substudy of retatrutide in people with type 2 diabetes has been published (Lancet Diabetes Endocrinol, 2025), but comprehensive lean mass data from the phase 3 obesity population is not yet available. Whether the glucagon component's effect on protein metabolism helps or hinders muscle preservation is an open question.

Cost and access: If approved, retatrutide's pricing and insurance coverage will determine real-world impact. Current GLP-1 agonists cost $800-1,300 per month at list price, and coverage remains inconsistent. A triple agonist with premium pricing could face even greater access barriers.

Approval timeline: Retatrutide is not FDA-approved. Seven TRIUMPH phase 3 trials are expected to report in 2026. Regulatory filing timelines have not been announced. For the latest on when retatrutide may be available, see our timeline article.

The Bottom Line

Retatrutide is the most potent anti-obesity peptide in clinical development, producing up to 28.7% body weight loss in phase 3 data. Its triple receptor mechanism (GLP-1 + GIP + glucagon) generates larger weight reductions and liver fat clearance than dual or single agonists. The tradeoff is higher discontinuation rates (up to 18.2%) and a new dysesthesia signal not seen with other incretin-based drugs. Phase 3 data is still emerging, with seven additional TRIUMPH trials expected to report in 2026. The drug is not approved anywhere in the world as of March 2026.

Frequently Asked Questions

How much weight can you lose on retatrutide?

In phase 3 data (TRIUMPH-4, December 2025), retatrutide 12 mg produced 28.7% mean body weight loss at 68 weeks, averaging 71.2 lbs. In the earlier phase 2 trial, Jastreboff et al. (2023) reported 24.2% weight loss at 48 weeks. 100% of participants on the highest dose lost at least 5% of body weight, and 83% lost at least 15%.

Is retatrutide better than semaglutide or tirzepatide?

Retatrutide produces larger average weight reductions than semaglutide (~16.9% at 68 weeks) or tirzepatide (~22.5% at 72 weeks) in cross-trial comparisons, but no head-to-head trials have been conducted. Retatrutide also has higher discontinuation rates due to adverse events (18.2% at 12 mg vs. lower rates for approved drugs) and a dysesthesia safety signal not seen with semaglutide or tirzepatide.

What are the side effects of retatrutide?

The most common side effects are gastrointestinal: nausea (up to 43.2%), diarrhea (33.1%), constipation (25.0%), vomiting (20.9%), and decreased appetite. A new safety signal, dysesthesia (abnormal skin sensation), was reported in up to 20.9% of participants on the highest dose in phase 3. Most adverse events were mild to moderate. Starting at a lower dose (2 mg) and titrating up partially mitigated early GI symptoms.

When will retatrutide be approved?

Retatrutide is not FDA-approved as of March 2026. The first positive phase 3 results (TRIUMPH-4) were announced in December 2025. Seven additional phase 3 trials are expected to report in 2026. Eli Lilly has not announced a regulatory filing date. Based on typical timelines, the earliest possible FDA approval would likely be late 2027 or 2028, depending on trial results and regulatory review.

What makes retatrutide different from other weight loss drugs?

Retatrutide is the first triple agonist, targeting GLP-1, GIP, and glucagon receptors in one molecule. Semaglutide targets only GLP-1. Tirzepatide targets GLP-1 and GIP. The glucagon receptor component is unique to retatrutide and appears to drive additional liver fat reduction and energy expenditure. Sanyal et al. (2024) showed up to 86% liver fat reduction, exceeding results from GLP-1 or dual agonists.

Does retatrutide help with liver disease?

In a phase 2a substudy, retatrutide 12 mg reduced liver fat by 86% at 48 weeks, with 93% of participants achieving normal liver fat levels. Sanyal et al. (2024) attributed this effect partly to the glucagon component stimulating hepatic fatty acid oxidation. Phase 3 trials for MASH (metabolic dysfunction-associated steatohepatitis) are underway. The current data is from patients with mostly mild liver disease, so efficacy in advanced fibrosis is unproven.